Table 1.
The clinical characteristics of the participants
| Mean(min-max) or N0. % | Total: n=143 | |||||
|---|---|---|---|---|---|---|
| Non-cancer: n=20 | EGC: n=31 | AGC: n=46 | PMGC: n=46 | |||
| Age, y | 66.45(51-87) | 60.90(45-79) | 59.48(40-84) | 59.54(32-81) | ||
| Male | 7(35%) | 24(77%) | 28(61%) | 27(59%) | 86 | |
| Female | 13(65%) | 7(33%) | 18(39%) | 19(41%) | 57 | |
| CEA | 1.66(1.02-4.25) | 2.98(0.20-25.10) | 4.74(0.50-55.90) | 16.49(0.40-372.80) | ||
| <5ng/mL | 20 | 27 | 36 | 34 | 117 | |
| ≥5ng/mL | 0 | 2 | 7 | 12 | 21 | |
| Absent | 0 | 2 | 3 | 0 | 5 | |
| CA19-9 | 13.05(5.61-26.97) | 10.16(0.90-35.50) | 88.54(0.60-2501.00) | 600.36(0.60-10000.00) | ||
| <37U/mL | 20 | 29 | 39 | 26 | 114 | |
| ≥37U/mL | 0 | 0 | 6 | 17 | 23 | |
| Absent | 0 | 2 | 1 | 3 | 6 | |
| CA125 | 7.18(3.61-10.96) | 13.59(3.70-49.10) | 14.24(3.40-44.40) | 103.52(7.50-156.00) | ||
| <35U/mL | 13 | 18 | 33 | 21 | 85 | |
| ≥35U/mL | 0 | 1 | 1 | 12 | 14 | |
| Absent | 7 | 12 | 12 | 13 | 44 | |
| AFP | 6.84(4.41-9.70) | 2.43(0.20-6.90) | 2.47(0.61-11.50) | 242.05(1.00-815.30) | ||
| <20ng/mL | 20 | 29 | 39 | 41 | 129 | |
| ≥20ng/mL | 0 | 0 | 0 | 1 | 1 | |
| Absent | 0 | 2 | 7 | 4 | 13 | |